Cupid Ltd Q1FY26 + FY25: Condoms, Court Cases & a 200x P/E Love Story
1. At a Glance
Cupid Ltd has pulled off what few FMCG names can: turning latex into a ₹5,600 Cr market cap story. Sales of ₹224 Cr and PAT of just ₹48 Cr are being valued at 118x earnings—apparently investors think this Nashik-based condom maker is India’s answer to Trojan + Colgate + Tinder all rolled into one. But behind the sugar rush lies reality: 36% promoter pledges, a 570-day cash conversion cycle, and a civil case hanging in Rajasthan court. In short: love is blind, but the balance sheet isn’t.
2. Introduction
Founded in 1993, Cupid began with one simple mission: provide protection in more ways than one. Three decades later, it produces male condoms (480 million annually), female condoms (52 million), lubricants (210 million sachets), and IVD test kits. Ninety percent of revenue comes from exports to 105+ countries, backed by WHO/UNFPA long-term contracts. Think of it as India’s latex ambassador.
FY25 saw revenue of ₹224 Cr and profit of ₹48 Cr. Impressive margins (32% OPM, 22% NPM) but laughably low absolute numbers—like a tiny kulfi shop with Michelin stars. Investors, however, have gone berserk: stock is up 216% in 6 months and 145% in 1 year. P/E? 118. Price-to-book? 16. Price-to-sales? 25.
Cupid is also diversifying into deodorants (because why not smell good after safe love), fragrances in Saudi Arabia, and even healthcare ventures in the Middle East. New promoters, the Halwasiyas, came in with a 42% stake in late 2023 and are expanding aggressively. But there’s drama: pledged promoter shares, convertible warrants at ₹1,751 (when CMP was way lower), and civil litigation with Vikas Lifecare.
Cupid is like Bollywood’s “Band Baaja Baaraat”: small-town roots, glamorous global stage, and a little bit of courtroom masala.
3. Business Model – WTF Do They Even Do?
Let’s explain Cupid to your lazy MBA friend. They have two main gigs:
Contraceptives (92% of revenue): Male and female condoms + lubricants. Export-led, with WHO/UNFPA contracts. Think of them as the “Maruti Suzuki” of latex: global buyers, steady volumes.
IVD kits (~2%): Pregnancy, HIV, dengue, malaria tests. Pandemic gave them a temporary Covid boost, but it’s now niche.
Others (6%): Includes new deodorants, fragrances, and diversification experiments.
The key hook: Cupid is the first company in the world with WHO/UNFPA prequalification for both male and female condoms. That means guaranteed demand from institutional buyers (Brazil, South Africa, Tanzania, UNFPA).
So, it’s a small-cap export FMCG play dressed up as a global healthcare brand. Except instead of toothpaste and shampoo, they sell latex balloons for adults.
